The association between oral candidiasis and severity of chemoradiotherapy-induced dysphagia in head and neck cancer patients: A retrospective cohort study

Hirotake Saito a,⇑, Ryusuke Shodo b, Keisuke Yamazaki c, Kouji Katsura d, Yushi Ueki b, Toshimichi Nakano e, Tomoya Oshikane e, Nobuko Yamana a, Satoshi Tanabe a, Satoru Utsunomiya f, Atsushi Ohta a, Eise Abe e, Motoki Kaidue e, Ryuta Sasamoto f, Hidefumi Aoyama e

a Department of Radiation Oncology, Niigata University Medical and Dental Hospital, 1-754 Asahimachi-dori, Chuo-ku, Niigata City, Niigata 951-8520, Japan
b Departments of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata City, Niigata 951-8510, Japan
c Department of Otolaryngology Head and Neck Surgery, Niigata University Medical and Dental Hospital, 1-754 Asahimachi-dori, Chuo-ku, Niigata City, Niigata 951-8520, Japan
d Department of Oral Radiology, Niigata University Medical and Dental Hospital, 1-754 Asahimachi-dori, Chuo-ku, Niigata City, Niigata 951-8520, Japan
e Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata City, Niigata 951-8510, Japan
f Department of Radiologic Technology, Niigata University Graduate School of Health Sciences, 2-746 Asahimachi-dori, Chuo-ku, Niigata 951-8518, Japan

A R T I C L E   I N F O

Article history:
Received 27 June 2019
Revised 21 October 2019
Accepted 26 October 2019
Available online 31 October 2019

Keywords:
Head and neck cancer
Dysphagia
Candidiasis

A B S T R A C T

Background and purpose: Concurrent chemoradiotherapy (CCRT) for head and neck cancer (HNC) is a risk factor for oral candidiasis (OC). As Candida spp. are highly virulent, we conducted a retrospective study to determine whether OC increases the severity of dysphagia related to mucositis in HNC patients.

Patients and methods: We retrospectively analyzed the cases of consecutive patients with carcinomas of the oral cavity, pharynx, and larynx who underwent CCRT containing cisplatin (CDDP) at our hospital. The diagnosis of OC was based on gross mucosal appearance. We performed a multivariate analysis to determine whether OC was associated with the development of grade 3 dysphagia in the Radiation Therapy Oncology Group (RTOG) Acute Toxicity Criteria. The maximum of the daily opioid doses was compared between the patients with and without OC.

Results: We identified 138 HNC patients. OC was observed in 51 patients (37%). By the time of their OC diagnosis, 19 (37%) had already developed grade 3 dysphagia. Among the 30 patients receiving antifungal therapy, 12 (40%) showed clinical deterioration. In the multivariate analysis, OC was independently associated with grade 3 dysphagia (OR 2.75; 95%CI 1.22–6.23; p = 0.015). The patients with OC required significantly higher morphine-equivalent doses of opioids (45 vs. 30 mg/day; p = 0.029).

Conclusion: Candida infection causes refractory dysphagia. It is worth investigating whether antifungal prophylaxis reduces severe dysphagia related to candidiasis.

1. Introduction

The standard curative approach for locally advanced head and neck cancer (HNC) is concomitant chemotherapy containing cisplatin (CDDP) and radiotherapy (RT; CCRT; concurrent chemoradiotherapy) [1,2]. One of the most frequent adverse events in CCRT for HNC is severe dysphagia related to mucositis [3,4]. CCRT-associated dysphagia is detrimental to the patients’ quality of life and increases the need for nutritional support, and >50% of the HNC patients undergoing CCRT require either enteral or parenteral nutrition (PN) [5,6]. Several approaches to the prevention of dysphagia have been explored, including intensity-modulated RT (IMRT) to reduce the dose to the pharyngeal constrictors, and de-escalated CCRT regimens [7–9]. However, these approaches are not recognized as standard treatments. It is crucial to elucidate the pathophysiology of CCRT-associated dysphagia and to establish an effective prophylactic approach [10].

Candida spp. colonize the upper aerodigestive tract in 70% of HNC patients [11,12]. Under physiological conditions, the virulence...
of *Candida* spp. is suppressed by mucosal epithelium and T cells [13], whereas the breakdown of the mucosal barrier leads to opportunistic candidiasis. Invasive candidiasis is associated with high morbidity and mortality rates [14]. It has thus been speculated that mucosal candidiasis causes oropharyngeal dysfunction in HNC patients undergoing CCRT. Busetto et al. conducted a prospective cohort study (MIR: Mucosis in Radiotherapy) and analyzed the relationship between the development of oral candidiasis (OC) and various toxicity outcomes in HNC patients undergoing curative RT [15]. They reported that among the patients with OC, the incidences of high-grade mucositis and dysphagia were significantly increased compared to the patients without OC.

Several studies have investigated OC in HNC patients undergoing RT [11,15–17]. These reports, which were written before CDDP-based CCRT had become a common practice, suffer from the heterogeneity of concomitant chemotherapy. The concomitant administration of RT and CDDP synergistically causes severe mucosal damage [18] and is thought to aggravate the symptoms of OC. We conducted the present study to elucidate (1) the severity of dysphagia associated with OC, (2) the impact of OC on the magnitude of dysphagia and the pain caused by mucositis, and (3) the response to antifungal agents among HNC patients undergoing CDDP-based CCRT.

2. Patients and methods

2.1. Eligible patients

Consecutive patients with carcinomas of the oral cavity, nasopharynx, oropharynx, hypopharynx, or larynx who were treated at our radiation oncology department during the 7+-year period between January 2011 and May 2018 were identified through an institutional cancer registry. The inclusion criteria were: (1) undergoing curative CCRT containing CDDP, and (2) being capable of oral intake at the start of the CCRT. Staging was done according to the 7th version of the American Joint Committee on Cancer (AJCC) TNM Classification. The patients' concurrent chemotherapy regimen was either (a) 5-fluorouracil (5FU) 700 mg/m² on days 1–5 and 29–33, plus CDDP 70 mg/m² on days 1 and 29, or (b) CDDP 80 mg/m² on days 1, 22, and 43. In general, we administered the CDDP + 5FU regimen from 2011 to 2014, and we administered the CDDP regimen in 2015 or later as concomitant chemotherapy.

All patients underwent CT simulation and 70 Gy in 35 once-daily fractions of RT delivered with 4–10 MV linear accelerators. The details of the dose prescription were 44–46 Gy to 35 elective regional nodes and 70 Gy to the gross tumor volume. The nasopharyngeal cancer patients treated in 2013 or later underwent IMRT, and the other patients underwent 3D conformal RT. The maximal dose to the spinal cord was kept at <50 Gy. In the IMRT planning, the mean dose to the parotid glands was kept at ≤25 Gy. No thresholds were set for the dose to the pharyngeal constrictors.

We used an opt-out approach in which eligible HNC patients and their family members were advised to contact the researchers only if they declined to be included in the study [19]. The study was approved by the institutional review board of our hospital (no. 2018–0127).

2.2. Data collection

All patients were hospitalized for the entire period from the start of their CCRT until their recovery of oral intake. Otolaryngologists examined the oropharyngeal mucosa with a fiberoptic scope 2 × /week. Specialist dentists or dental hygienists provided oral care 1 × /week. Acetaminophen and long-acting and short-acting opioids were prescribed based on the severity of the pain caused by mucositis [20]. The diagnosis of OC was based on the gross mucosal appearance, and mycological confirmation was not mandatory [15,21]. It was left to each physician’s judgement whether to initiate antifungal treatment. Both topical and systemic antifungal agents were used [22].

A radiation oncologist (SH) reviewed all of the patients’ medical charts. The severity of dysphagia was graded according to the Radiation Therapy Oncology Group (RTOG) Acute Toxicity Criteria [23]. At our institution, the use of a specific mucositis severity scale is not mandatory; we used the opioid dose as a surrogate for the severity of the pain caused by mucositis. The maximal daily dose of long-acting opioids was converted into the intravenous morphine-equivalent dose [24,25]. In the patients who developed OC, the RTOG grade of dysphagia was recorded at the time of OC diagnosis. The patients’ responses to antifungal agents was judged retrospectively: “deterioration” corresponded to the worsening of mucosal lesions, the increase in opioid doses, or the initiation of nutritional therapy within 14 days of antifungal treatment [26], and “improvement” corresponded to the complete or partial resolution of symptoms without deterioration. The other responses were classified as “indistinguishable”.

2.3. Statistical analyses

We first used Fisher’s exact test to investigate the relationships between the development of OC and various clinical factors including age, gender, chemotherapy, performance status (PS), primary site, presence of diabetes mellitus (DM), and stage. We tested the

| Baseline characteristics of the HNC patients (n = 138). |  
| --- | --- |  
|  | CDDP + RT | CDDP + 5FU + RT |  
| n = 88 | n = 50 |  
| **Age (median, range)** | 65 (37–78) | 66 (32–78) | 0.635  
| **Gender** |  
| Male | 77 (88%) | 46 (92%) | 0.572  
| Female | 11 (12%) | 4 (8%) |  
| **Histology** |  
| SqCC | 88 (100%) | 49 (98%) | 0.362  
| AC | 0 | 1 (2%) |  
| **Primary site** |  
| Hypopharynx | 35 (40%) | 17 (34%) | 0.9  
| Larynx | 8 (9%) | 4 (8%) |  
| Nasopharynx | 17 (19%) | 13 (26%) |  
| Oral cavity | 3 (3%) | 2 (4%) |  
| Oropharynx | 25 (28%) | 14 (28%) |  
| **Stage** |  
| II | 11 (12%) | 13 (26%) | 0.033  
| III | 29 (33%) | 8 (16%) |  
| IV | 48 (55%) | 29 (58%) |  
| **ECOG PS** |  
| 0 | 7 (8%) | 2 (4%) | 0.771  
| 1 | 79 (90%) | 47 (94%) |  
| 2 | 2 (2%) | 1 (2%) |  
| **RT techniques** |  
| 3DCRT | 71 (81%) | 44 (88%) | 0.345  
| IMRT | 17 (19%) | 6 (12%) |  
| **Dose (Gy; median, range)** | 70 (66–70) | 70 (60–70) | 0.653  
| **YOT** |  
| 2011 | 0 | 14 (28%) | NA  
| 2012 | 0 | 7 (14%) |  
| 2013 | 6 (7%) | 8 (16%) |  
| 2014 | 3 (3%) | 11 (22%) |  
| 2015 | 13 (13%) | 7 (14%) |  
| 2017 | 29 (33%) | 1 (2%) |  
| 2018 | 7 (8%) | 0 |  

Abbreviations: HNC = head and neck cancer, CDDP = cisplatin, RT = radiotherapy, 5FU = 5-fluorouracil, SqCC = squamous cell carcinoma, AC = adenocarcinoma, ECO-G = Eastern Cooperative Oncology Group, PS = Performance Status, 3DCRT = 3D conformal radiotherapy, IMRT = intensity-modulated radiotherapy, YOT = year of treatment.
We identified 471 consecutive HNC patients, and 138 met the inclusion criteria (Fig. A1). There were no significant differences in the baseline patient demographics between the group of patients treated with RT + 5FU + CDDP (n = 50) and the group of patients treated with RT + CDDP (n = 88) (Table 1). The median follow-up period for all patients, which was calculated from the first day of CCRT, was 26.1 months. All eligible patients were hospitalized throughout their CCRT, and the complete medical chart was available for all patients. Ninety-two patients (67%) required either PN or tube feeding and were judged as having developed grade 3 dysphagia.

OC was observed in 51 patients (37%). Fifty patients were diagnosed with pseudomembranous OC, and one patient was diagnosed with hyperplastic OC. No patients were diagnosed with erythematous OC. Mycological culture tests using oral swabs were performed in eight patients, and C. albicans was recovered from all specimens. The median cumulative dose at the time of OC diagnosis was 38 Gy (range 6–70 Gy). These patients were diagnosed with OC at a median of CCRT day 29 (range 5–83). There were no significant differences in the incidence of OC by the primary site, stage, age, or chemotherapy (Table 2).

The RTOG grade of dysphagia at the time of OC diagnosis was grade 0–1 in 11 patients (22%), grade 2 in 21 patients (41%), and grade 3 in 19 patients (37%). Among the 32 patients whose dysphagia grade was 0–2 at the time of OC diagnosis, 21 patients (66%) developed grade 3 dysphagia. Topical antifungal agents were administered in 28 patients. Two patients underwent systemic azole therapy; one patient received 200 mg/day of itraconazole syrup for 7 days, and the other received 200 mg/day of intravenous fluconazole for 13 days. The topical agents failed to improve the symptoms of OC in 10 patients (36%), and the systemic azoles failed in both patients (100%). Five of the 28 patients receiving topical agents showed an improvement of symptoms.

The patients with OC developed grade 3 dysphagia significantly more frequently compared to the patients without OC (78% vs. 60%, p = 0.026) (Table 3). Similarly, the stage II patients tended to have a higher incidence of grade 3 dysphagia compared to the stage III patients (83% vs. 54%, Bonferroni-adjusted p = 0.081). In the multivariate analysis, OC alone was independently associated with grade 3 dysphagia (OR 2.75, 95%CI 1.22–6.23, p = 0.015) (Table 4).

We drew the histogram of the maximum of daily morphine-equivalent doses of opioids for the OC group and the non-OC group, respectively. The opioid dose peak was observed in the 40–60 mg interval in the OC group, whereas the peak was observed in the
Treatment outcomes of OC in precedent clinical trials.

| Patients          | Drug      | Daily dose (mg) | Duration (days) | Clinical cure rate (%) | Author and publication year | Reference No. |
|-------------------|-----------|-----------------|-----------------|------------------------|-----------------------------|---------------|
| AIDS              | Fluconazole | 100             | 14              | 82.5                   | Vazquez et al. 2006         | [26]          |
| AIDS              | Fluconazole | 100             | 14              | 87                     | Graybill et al. 1998        | [33]          |
| AIDS              | Intracnazole | 200            | 14              | 97                     |                             |               |
| AIDS              | Intracnazole | 200             | 7               | 86                     |                             |               |
| AIDS              | Fluconazole | 150             | 14              | 95.5                   | Hamza et al. 2008           | [34]          |
| AIDS              | Fluconazole | 100             | 14              | 87                     | Pons et al. 1997            | [35]          |
| RT for HNC        | Miconazole | 50              | 14              | 52.5                   | Bensadoun et al. 2008      | [36]          |
| Malignant tumor   | Miconazole gel | 500           | 14              | 45.4                   | Oude Lashof et al. 2004    | [37]          |
| CCRT for HNC      | Fluconazole | 200             | 13              | 0                      | Present study               |               |
|                   | Intracnazole | 200            | 7               | 0                      |                             |               |

Abbreviations: AIDS = acquired immunodeficiency syndrome, RT = radiotherapy, HNC = head and neck cancer, OC = oral candidiasis, MAT = mucoadhesive tablet, CCRT = concurrent chemoradiotherapy.
yis [17]. However, mucositis-associated dysphagia and pain were not evaluated in these studies. A prospective trial is necessary to determine whether antifungal prophylaxis reduces the severity of pain and dysphagia related to mucositis in HNC patients.

The present study has several limitations. First, the study dealt with a small cohort with heterogenous characteristics and treatment details (different primary tumor sites, IMRT vs. 3DCRT, differing doses to pharyngeal constrictors, etc.) We performed a multivariate analysis to reduce these biases. Second, the patients’ daily medical charts generally lack microbiological data. Third, the response to antifungal treatment was not mentioned in the medical charts and was judged retrospectively. Nevertheless, it was clear that both two patients treated with systemic azole therapy showed clinical failure, which implies the refactoriness of chemoradiation-associated OC. Despite these limitations, we consider that our study revealed clinically relevant information, and our findings pose an important question that should be addressed in a prospective trial; i.e., whether antifungal prophylaxis reduces the severity of pain and dysphagia related to mucositis in HNC patients.

5. Conclusions

Candida infection aggravated the severity of pain and dysphagia related to mucositis during CCRT for head and neck cancer. One-third of the patients with OC in our cohort had already developed high-grade dysphagia by the time of their diagnosis of OC. CCRT-associated OC was refractory to antifungal treatment. As the early diagnosis of OC is difficult, it is worth investigating whether anti-fungal prophylaxis reduces the severity of dysphagia related to candidiasis.

Funding support

The present work was supported by a grant from the Japanese Society for Promotion of Science KAKENHI, grant #19K17262.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix

Fig. A1.

Fig. A1. CONSORT diagram. Abbreviations; RT = radiotherapy, CDDP = cisplatin, 5FU = 5-fluorouracil.

References

[1] Lucar B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol 2017;18(9):1221–37.
[2] Piguen JP, le Maire A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92(1):4–14.
[3] Nguyen NP, Moltz CC, Frank C, et al. Dysphagia following chemoradiation for locally advanced head and neck cancer. Ann Oncol 2004;15(3):383–8.
[4] Rosenthal DI, Lewin JS, Eisbruch A. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 2006;24(17):2636–43.
[5] Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 2018;393(9915):40–50. https://doi.org/10.1016/S0140-6736(18)32779-X.
[6] Noronha V, Joshi A, Patil VM, et al. Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin Oncol 2018;36(11):1064–72.
[7] Chen AM, Felix C, Wang PC, et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol 2017;18(6):803–11.
[8] Fung PY, Kim HM, Lyden TH, et al. Immune-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol 2010;28(16):2732–8.
[9] Mesi R, Taberna M. HPV-related oropharyngeal carcinoma de-escalation protocols. Lancet Oncol 2017;18(6):704–5.
[10] Greco E, Simic T, Ringsash J, et al. Dysphagia Treatment for Patients With Head and Neck Cancer Undergoing Radiation Therapy: A Meta-analysis Review. Int J Radiat Oncol Biol Phys 2018;101(2):421–44.
[11] Dahiya MC, Redding SW, Zellars RC, et al. Oropharyngeal candidiasis caused by non-albicans yeasts in patients receiving external beam radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2003;57(1):79–83.
[12] Redding SW, Zellars RC, Kirkpatrick WR, et al. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol 1999;37(12):3896–900.
[13] Netea MG, Joosten LA, van der Meer JW, et al. Immune defence against Candida fungal infections. Nat Rev Immunol 2015;15(10):630–42.
[14] Brown GD, Denning DW, Gow NA, et al. Hidden killers: human fungal infections. Sci Transl Med 2012;4(165):165rv13.
[15] Busetto M, Fusco V, Corbella F, et al. Predictive factors for oropharyngeal mycosis during radiochemotherapy for head and neck carcinoma and consequences on treatment duration. Results of mycosis in radiotherapy (MIR): a prospective longitudinal study. Radiother Oncol 2013;109(2):303–10.
[16] Gilgorev J, Bastit L, Gervais H, et al. Prevalence and treatment management of oropharyngeal candidiasis in cancer patients: results of the French CANDIDOSCOPE study. Int J Radiat Oncol Biol Phys 2011;80(2):532–9.
[17] Rao NG, Han G, Greene JN, et al. Effect of prophylactic fluconazole on oral mucositis and candidiasis during radiation therapy for head-and-neck cancer. Pract Radiat Oncol 2013;3(3):229–33.
[18] Sanguineti G, Sormani MP, Marur S, et al. Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2012;83(1):235–42.
[19] Lacey RJ, Willie R, Wynne-Jones G, et al. Evidence for strategies that improve recruitment and retention of adults aged 65 years and over in randomised trials and observational studies: a systematic review. Age Ageing 2017;46(5):905–903.
[20] Ženda S, Matsuura K, Tachibana H, et al. Multicenter phase II study of an opioid-based pain control program for head and neck cancer patients receiving chemoradiotherapy. Radiother Oncol 2011;101(3):410–4.
[21] Farah CS, Lynch N, McCullough MJ. Oral fungal infections: an update for the general practitioners. Aust Dent J 2010;55(Suppl 1):48–54.
[22] Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62(6):e1–e44.
[23] Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31(5):1341–6.
[24] Le QT, Kim HE, Schneider CJ, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol 2011;29(20):2808–14.
[25] Ellings LS, Cooksey CD, Chambers MS, et al. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 2007;68(4):1110–20.
[26] Vanza JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006;42(8):1794–9.
[27] Wang SL, Liao Z, Vaporiyan AA, et al. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 2006;64(3):692–9.
[28] Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013;48(3):452–8.
Moyes DL, Wilson D, Richardson JP, et al. Candidalysin is a fungal peptide toxin critical for mucosal infection. Nature 2016;532(7597):64–8.

Soysa NS, Samaranayake LP, Ellepola AN. Antimicrobials as a contributory factor in oral candidiasis—a brief overview. Oral Dis 2008;14(2):138–43.

Dodd CL, Greenspan D, Katz MH, et al. Oral candidiasis in HIV infection: pseudomembranous and erythematous candidiasis show similar rates of progression to AIDS. AIDS 1991;5(11):1339–43.

Redding SW, Bailey CW, Lopez-Ribot JL, et al. Candida dubliniensis in radiation-induced oropharyngeal candidiasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91(6):659–62.

Graybill JR, Vazquez J, Darouiche RO, et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998;104(1):33–9.

Hamza OJ, Matee MI, Bruggemann RJ, et al. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial. Clin Infect Dis 2008;47(10):1270–6.

Pons V, Greenspan D, Lozada-Nur F, et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 1997;24(6):1204–7.

Bensadoun RJ, Daoud J, El Gueddari B, et al. Comparison of the efficacy and safety of miconazole 50-mg mucosal adhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer 2008;112(1):204–11.

Oude Lashof AM, De Bock R, Herbrecht R, et al. An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. Eur J Cancer 2004;40(9):1314–9.

Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003;67(3):400–28.

Reichart PA, Philipsen HP, Schmidt-Westhausen A, et al. Pseudomembranous oral candidiasis in HIV infection: ultrastructural findings. J Oral Pathol Med 1995;24(6):276–81.

Popovtzer A, Cao Y, Feng FY, et al. Anatomical changes in the pharyngeal constrictors after chemo-irradiation of head and neck cancer and their dose-effect relationships: MRI-based study. Radiother Oncol 2009;93(3):510–5.

Nicolatou-Galitis O, Velegraki A, Sotiropoulou-Lontou A, et al. Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy. Support Care Cancer 2006;14(1):44–51.